NICE set to endorse talazoparib for adults with BRCA 1 or 2 mutated HER2-negative locally advanced o...
Read moreWe're thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We'll...
Read moreThis research aims to understand if just three PICOs are feasible by analysing recent HTA assessment...
Read moreWe explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...
Read moreIn a joint report Lif, the New Therapeutics (NT) Council and representatives of the regions have pro...
Read moreWe explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreNICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...
Read moreIdentification of current cost of oncology care treatment options.
Read more